Cargando…
Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues
Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients, eventually causing relapse. Repeated purine anal...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418384/ https://www.ncbi.nlm.nih.gov/pubmed/34535326 http://dx.doi.org/10.1016/j.blre.2021.100888 |